A Study to Identify Breast Cancer (IDBC) (IDBC)
Investigation of a Novel Blood Test to Identify Breast Cancer (IDBC)
Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed.
The primary objective of this study is to validate Syantra DX Breast Cancer methodology and biomarker panel using prospective samples, well categorized by diagnostic imaging scores, pathology outcomes, and subject characteristics.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The current project is aimed at validating Syantra DX Breast Cancer in a screening population. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed, and is described below.
The study seeks to evaluate performance of Syantra DX Breast Cancer in prospective samples and to optimize test methodology and biomarkers. Key to performance of the study is recruitment of women who provide a blood sample around the time of a screening mammogram. Some women have received an abnormal mammography report, and have been classified under the UK Royal College of Radiologists Breast Group (RCRBG) or BI-RADS scoring system in categories 3 - 5. This will support the ability to employ the test for breast cancer detection in a screening/call-back environment. To complete the study cohort, additional women will be recruited from the population who have normal or benign mammography results (RCRBG category 1 and 2), and/or a recent normal physical breast exam, with no history of breast cancer. Blood samples will be acquired from all women following completion of an informed consent procedure.
For those with an abnormal mammogram, blood will be drawn before a biopsy is performed. All sample information will be de-identified, and the samples will be processed and analysed according to Syantra DX Breast Cancer standard operating procedures. These procedures include extracting sample RNA and aliquoting for storage in a manner that maintains sample anonymity. All processing and analysis will be conducted in a blind environment without knowing the associated RCRBG or pathology outcomes for any samples. Only after testing is complete will sample classifications be revealed. Syantra DX Breast Cancer results will then be compared to RCRBG/BI-RADs, biopsy and pathology data to determine performance, and statistics will be calculated.
There is an optional part of the study procedure that is included as 'additional research'. A specific question seeking approval for the additional research is included on the study consent form. For individuals who agree to participate in the additional research, material extracted from their blood sample will be stored for additional investigations.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Linda Bailey
- Phone Number: 0161 291 4492
- Email: linda.bailey3@mft.nhs.uk
Study Contact Backup
- Name: Natasha Jones
- Phone Number: 0161 291 4045
- Email: Natasha.Jones@mft.nhs.uk
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada
- Recruiting
- Alberta Cancer Research Biobank
-
Contact:
- Shannon Brown
- Phone Number: 403-521-3604
- Email: Shannon.Brown@cancercarealberta.ca
-
Contact:
- Danielle Simonot
- Email: Danielle.Simonot@cancercarealberta.ca
-
Principal Investigator:
- Kristina Rinker, PhD
-
Sub-Investigator:
- Bobbi-Jo Docktor, MD
-
Sub-Investigator:
- Don Morris, MD
-
-
-
-
-
Soeul, South Korea
- Completed
- Severance Hospital
-
-
-
-
-
Manchester, United Kingdom, M23 9LT
- Recruiting
- Wythenshawe Hospital, Southmoor Road
-
Principal Investigator:
- Nigel Bundred, MD
-
Contact:
- Natasha Jones
- Email: Natasha.Jones@mft.nhs.uk
-
Manchester, United Kingdom, M23 9LT
- Recruiting
- North Manchester General Hospital
-
Contact:
- Natasha Jones
- Email: Natasha.Jones@mft.nhs.uk
-
Principal Investigator:
- Nigel Bundred
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria
- Aged 30-75 years
- Normal breast examination - No cancer detected/suspected by physical exam, diagnostic radiology or screening mammography
- Women with suspected Invasive Breast Cancer
- Individuals with an abnormal or suspicious mammogram
- Abnormal screening mammogram with suspected benign breast disease or proliferative changes
Exclusion criteria
- Cancer diagnosis
- Male
- Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)
- Previous history of any cancer
- Concomitant or other concurrent anti-cancer therapy
- Inoperable or inflammatory breast cancer
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Borderline (Atypica and LCIS) Population
Women with borderline pathological B3 lesions (suspected atypia Ductal or Lobular and benign proliferative disease without DCIS or invasion) Inclusion criteria
Exclusion criteria
|
Blood test for detecting the presence of breast cancer.
|
|
Control Population
Healthy Controls Inclusion criteria
Exclusion criteria
|
Blood test for detecting the presence of breast cancer.
|
|
Investigational Population
Suspected Invasive Breast Cancer (any size) or DCIS (pre-invasive) are of particular interest. Women with abnormal screening mammograms (R3-5) recalled for further investigation. Inclusion criteria
Exclusion criteria
|
Blood test for detecting the presence of breast cancer.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance of the Syantra DX Breast Cancer test as assessed by sensitivity and specificity
Time Frame: through completion of the study. Individual participant data for primary outcome recorded about 18 months from enrollment.
|
The number of participants that test positive or negative for breast cancer with the Syantra DX Breast Cancer test and their breast cancer status as assessed by mammography or pathology.
|
through completion of the study. Individual participant data for primary outcome recorded about 18 months from enrollment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modulate test methodology to account for differences between retrospective and prospective samples
Time Frame: through completion of the study, approximately eighteen months
|
Determine the sensitivity and specificity of the assay with biomarker panel modifications.
|
through completion of the study, approximately eighteen months
|
|
Performance of the Syantra DX Breast Cancer test in prediction of molecular subtype of breast cancer as assessed by pathology
Time Frame: through completion of the study, approximately eighteen months
|
Correlate the performance of the test to molecular characterizations of identified cancers as assessed by pathology of tissue from biopsy or resection.
|
through completion of the study, approximately eighteen months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nigel Bundred, MD, Manchester University NHS Foundation Trust
- Study Director: Cliona Kirwin, MD, Manchester University NHS Foundation Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 241391
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.